Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion

Thomas Delong(University of Colorado Anschutz Medical Campus), Timothy A. Wiles(University of Colorado Anschutz Medical Campus), Rocky L. Baker(University of Colorado Anschutz Medical Campus), Brenda Bradley(University of Colorado Anschutz Medical Campus), Gene Barbour(University of Colorado Anschutz Medical Campus), Richard Reisdorph(University of Colorado Denver), Michael Armstrong(University of Colorado Denver), Roger Powell(University of Colorado Denver), Nichole Reisdorph(University of Colorado Denver), Nitesh Kumar(St Vincents Institute of Medical Research), Colleen M. Elso(St Vincents Institute of Medical Research), Megan DeNicola(University of Massachusetts Chan Medical School), Rita Bottino(Allegheny Health Network), Alvin C. Powers(VA Tennessee Valley Healthcare System), David M. Harlan(University of Massachusetts Chan Medical School), Sally C. Kent(University of Massachusetts Chan Medical School), Stuart I. Mannering(St Vincent's Hospital Melbourne), Kathryn Haskins(University of Colorado Anschutz Medical Campus)
Science
February 12, 2016
Cited by 490

Abstract

T cell-mediated destruction of insulin-producing β cells in the pancreas causes type 1 diabetes (T1D). CD4 T cell responses play a central role in β cell destruction, but the identity of the epitopes recognized by pathogenic CD4 T cells remains unknown. We found that diabetes-inducing CD4 T cell clones isolated from nonobese diabetic mice recognize epitopes formed by covalent cross-linking of proinsulin peptides to other peptides present in β cell secretory granules. These hybrid insulin peptides (HIPs) are antigenic for CD4 T cells and can be detected by mass spectrometry in β cells. CD4 T cells from the residual pancreatic islets of two organ donors who had T1D also recognize HIPs. Autoreactive T cells targeting hybrid peptides may explain how immune tolerance is broken in T1D.


Related Papers

No related papers found

Powered by citation graph analysis